amp biosimilars AG / Key word(s): Agreement/Joint Venture

2015-06-10 / 07:00

amp biosimilars AG: Second biosimilar product successfully out-licensed

Second successful out-licensing within brief period

Leading position in Asia

Potential earnings exceed hundreds of millions of euros

Further out-licensing in pipeline

Hamburg, Germany, June 10, 2015 – amp biosimilars AG (ISIN: DE000A0SMU87), a company focused on developing high quality biosimilars, is now able to report a second successful out-licensing shortly after its first successful biosimilar out-licensing. The second successfully out-licensed biosimilar in the product pipeline is ABY-021, which is a humanized monoclonal antibody for treating immunological symptoms.

The out-licensing partner is once again a leading medium-sized Chinese pharmaceuticals company, which has thus secured the rights to market ABY-021 in China. The licensing helps amp biosimilars to secure complete financing for the development and approval processes starting from Clinical Phase I on through to production and marketing of the biosimilar in China. The global rights outside of China remain with amp biosimilars and allow the issuance of further licenses to other pharmaceutical companies around the world, creating potential for additional earnings.

In addition to the financing of product development up to the approval process, amp biosimilars will receive royalties starting from the marketing launch of the biosimilar, which may be worth hundreds of millions of euros.

“The second out-licensing in such a short period of time is a very important milestone for amp biosimilars,” explains Dr. Marc W. Hentz, Chief Executive Officer of amp biosimilars AG. “Our partners are acknowledging that our unique approach means we can develop biosimilars more affordably and efficiently than any of our competitors and that we have wide-ranging experience and the extensive technological skill in the biosimilar field.

In addition we are also confirming our decisive competitive advantage: Strategic access to the fastest growing pharmaceuticals markets. Our company can thus outpace growth on the overall market.”

“This out-licensing is incredibly important for our company and a huge success. The deal illustrates our importance in the market place and is recognition of our business model as it differs from many competitors like for example Coherus, Sandoz or Quintiles by focusing on ‘pharmerging markets’,” adds Dr. Knut Adermann, Chief Technology Officer at amp biosimilars AG. “It is an impressive sign that we have the unique opportunity to grow faster than other market participants in this very interesting segment.”

amp biosimilars views this second out-licensing within a short period as confirmation of the strategic focus with further transactions to follow soon. The initial out-licensing of ABY-018, which amp biosimilars disclosed a few weeks ago, provided shareholders with undiluted project financing up to approval as well as cumulative earnings potential worth hundreds of millions of euros. In addition, amp biosimilars will now have a leading position on the Chinese biosimilars market, which will become the largest in the world by 2017 and thus succeed Europe.

About biosimilars:
Biosimilars are imitations of existing bio-pharmaceuticals and constitute one of the fastest growing segments of the pharmaceutical industry. Sales are expected to increase in the next 10 years from the current 3 billion US dollars to an estimated 100 billion US dollars. Biosimilars are more affordable than original products and provide access to new therapies for a far greater number of patients. Biosimilars represent potential savings of 250 billion US dollars by 2024 in the US healthcare system alone. Biosimilars open new markets with significantly lower development risks thanks to the use of well-known active ingredients.

About amp biosimilars AG:
amp biosimilars AG develops high quality biosimilars to meet growing demand on global therapeutic markets and is one of the most innovative and dynamic biosimilar companies in Europe. The company is headquartered in Hamburg and run by a team of leading industry experts. The development of a wide variety of biosimilars will provide patients around the world with access to life-improving and life-saving therapies. The combination of a research platform with state-of-the-art analytics, process technology and clinical expertise as well as regulatory know-how, makes amp biosimilars AG one of the leading companies for biosimilar development and marketing. Thanks to an international network of leading pharmaceutical companies, amp biosimilars AG also has direct access to the strongest growing markets in the world. With this approach amp biosimilars AG has a key position in one of the fastest growing life science markets in the near future. amp biosimilars AG has been listed on the Munich Stock Exchange since April 1, 2015. For more information please go to

MC Services AG
Fabian Lorenz
Tel: +49 211 529252-28


2015-06-10 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at and

366827  2015-06-10 

This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG and does not constitute a prospectus of Northern Data AG. The information contained in this press release is not intended to form the basis of any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As with all business and investment matters, please consult qualified professional advice. This release and the information contained herein are not for distribution, directly or indirectly, in or into the United States of America, Canada, Australia or Japan.